Prolongation of Cardiac Xenograft Survival by Depletion of Complement

Leventhal, Joseph R.; Dalmasso, Agustin P.; Cromwell, John W.; Platt, Jeffrey L.; Manivel, Carlos; Bolman, R. Morton; Matas, Arthur J.

doi:10.1097/00007890-199304000-00033

Cited by 289 publications

(118 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…CVF has been safely administered in a variety of experiments to block the C cascade in animals. [34][35][36][37] Thus, it may provide an additional method of protecting baculovirus vectors from C inactivation.…”

Section: Figure 5 Baculovirus Survival In Human Plasma and Blood Bacmentioning

confidence: 99%

Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system

Hofmann¹,

1998

View full text Add to dashboard Cite

Section: Figure 5 Baculovirus Survival In Human Plasma and Blood Bacmentioning

confidence: 99%

Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system

Hofmann¹,

1998

View full text Add to dashboard Cite

“…Afin de prévenir l'apparition du rejet hyperaigu, il est possible de dépléter les anticorps xénoréactifs par plasmaphérèse [16] ou immunoadsorption. Les inhibiteurs du complément tels que le facteur de venin de cobra [17], le CR1 soluble (complement receptor 1) [18] et le sulfate de dextran [19] prolongent éga-lement la survie du greffon. L'activité du complément sur l'endothélium est normalement contrôlée par des protéines régu-latrices telles que le DAF (decay accelerating factor), le CD59 ou la MCP (membrane cofactor protein).…”

Section: Quelle Approche Pour Quel Type De Rejet?unclassified

Les xénogreffes finiront-elles par être acceptées ?

Séveno

Fellous²,

Ashton‐Chess

et al. 2005

Med Sci (Paris)

View full text Add to dashboard Cite

“…It has been shown previously that even with control of hyperacute rejection, cardiac xenograft rejection is associated with intravascular IgM deposition and extensive cellular infiltration (11). To investigate whether subclinical damage to the transplanted xenografts was present, donor-specific xenografts were electively removed at fixed time points and assessed for histologic evidence of cellular or humoral rejection between 16 and 200 days following transplantation into mixed xenogeneic chimeras.…”

Section: Evidence For Cellular and Humoral Tolerance Toward Donorspecmentioning

confidence: 99%

Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts

Colson

Huang

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

Xenotransplantation has been suggested as a potential solution to the critical shortage of donor organs. However, success has been limited by the vigorous rejection response elicited against solid organs transplanted across species barriers. Mixed xenogeneic bone marrow chimeras resulting from the transplantation of a mixture of host and donor marrow (B10 mouse + F344 rat → B10 mouse) results in donor-specific cross-species transplantation tolerance for subsequent nonvascularized skin and islet grafts. Furthermore, compared with fully xenogeneic chimeras (rat → mouse), mixed xenogeneic chimeras exhibit superior immunocompetence for infectious agents in vivo and in vitro, suggesting that the immune system is intact. The ability to establish long-term humoral and cellular tolerance for primarily vascularized xenografts in vivo, in the setting of both recipient and donor Ig and effector cell production, has not previously been characterized. Mixed xenogeneic chimeras exhibit donor-specific humoral tolerance as evident by the absence of anti-donor Ab and Ab-dependent donor-specific cytotoxicity in vitro and intravascular IgM deposition within donor-strain (F344) cardiac xenografts in vivo. F344 cardiac xenografts are accepted (median ≥180 days) without clinical or histologic evidence of rejection, suggesting cellular tolerance. In contrast, MHC-disparate third-party mouse (B10.BR) and rat (ACI or WF) grafts are rejected (median of 23 and 41 days, respectively) in association with extensive mononuclear cell infiltration and vascular deposits of mouse IgM. These results demonstrate that mixed xenogeneic chimerism establishes donor-specific humoral and cellular tolerance and permits the successful transplantation of even primarily vascularized xenografts in the setting of intact Ab production.

show abstract

Prolongation of Cardiac Xenograft Survival by Depletion of Complement

Cited by 289 publications

References 0 publications

Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system

Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system

Les xénogreffes finiront-elles par être acceptées ?

Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts

Contact Info

Product

Resources

About